Drugmakers have greeted 2025, implementing price hikes for 583 products within the first two days of the new year, according ...

Merck just rewarded its shareholders again with a dividend hike. This Dow stock has come with a quarterly dividend for almost ...

Most experience exists for sitagliptin (Merck) and vildagliptin (Novartis), which both have a long duration of action, allowing once-daily administration. In drug-naïve subjects with type 2 ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate prices concessions, Bloomberg reported. The company told USA TODAY that it would ...

With a market cap of $252.6 billion, Rahway, New Jersey-based Merck & Co., Inc. (MRK) is a global leader in the healthcare ...

Meanwhile Steglujan (ertugliflozin+sitagliptin), a fixed dose combination combining the SGLT2 with Merck’s Januvia, is approved in type 2 disease when patients who need both drugs. Ertugliflozin ...

Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

Merck wins UK approval for lung disease drug acquired in $11 billion deal Future of Healthcategory· December 31, 2024 The U.S. Food and Drug Administration said on Friday that it has approved an ...

The Chinese contract drugmaker will sell its vaccine factory in Dundalk, Ireland, to U.S.-based Merck for about $500 million, it said in an exchange filing late Monday. The facility, with a net ...

Merck booked just under $600 million last year in alliance revenues from the pair, but its attention is now moving to new therapies including sotatercept, a TGF-beta-targeting PAH drug Merck ...